SCHEMBL20227693

SCHEMBL20227693

O=c1c2ccccc2c2ccccc2n1-c1cccc(-c2ccc3c(-c4ccccc4)c4ccccc4c(-c4ccccc4)c3c2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.53
MAPK1 P28482 1/20 0.45
PDE10A Q9Y233 1/20 0.41
KDM4E B2RXH2 4/20 0.40
ATM Q13315 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
GAA P10253 3/20 0.40
MEN1 O00255 2/20 0.40
ALDH1A1 P00352 4/20 0.39
HSD17B10 Q99714 2/20 0.39
POLB P06746 1/20 0.39
TSHR P16473 1/20 0.39
BRCA1 P38398 1/20 0.39
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
RCE1 Q9Y256 1/20 0.38
CYP1A2 P05177 1/20 0.38
GLA P06280 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20227519 0.92 KMT2A (0.56) KMT2AMAPK1PDE10AKDM4EATM
SCHEMBL20227515 0.92 KMT2A (0.58) KMT2AMAPK1PDE10AKDM4EATM
SCHEMBL20227682 0.91 KMT2A (0.56) KMT2AMAPK1KDM4EATML3MBTL1
SCHEMBL20227514 0.91 KMT2A (0.51) KMT2AMAPK1PDE10AKDM4EATM
SCHEMBL20227686 0.91 KMT2A (0.55) KMT2AMAPK1KDM4EATML3MBTL1
SCHEMBL26046196 0.90 KMT2A (0.49) KMT2AMAPK1PDE10AKDM4EATM
SCHEMBL20227701 0.90 KMT2A (0.52) KMT2AMAPK1KDM4EATML3MBTL1
SCHEMBL20227732 0.90 KMT2A (0.47) KMT2AMAPK1PDE10AKDM4EATM
SCHEMBL20227709 0.90 KMT2A (0.53) KMT2AMAPK1PDE10AKDM4EATM
SCHEMBL20227689 0.89 KMT2A (0.56) KMT2AMAPK1KDM4EATML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11713319-B2 Compounds having valerolactam structures MERCK PATENT GMBH (DE) 2023-08-01 US disclosed
US-11713319-B2 Compounds having valerolactam structures MERCK PATENT GMBH (DE) 2023-08-01 US disclosed
US-20200031827-A1 COMPOUNDS HAVING VALEROLACTAM STRUCTURES MERCK PATENT GMBH (DE) 2020-01-30 US disclosed
WO-2018099846-A1 COMPOUNDS HAVING VALEROLACTAM STRUCTURES MERCK PATENT GMBH (DE) 2018-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11713319-B2 Compounds having valerolactam structures ACE, CYP3A4, CYP2D6 KMT2A 1161/4885MAPK1 2970/4885PDE10A 3215/4885
US-20200031827-A1 COMPOUNDS HAVING VALEROLACTAM STRUCTURES ACE, CYP3A4, CYP2D6 KMT2A 1161/4885MAPK1 2970/4885PDE10A 3215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.